Cancer vaccines: A critical review on clinical impact

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 1, 2004, Pages 17-26

  Bitton, Roberto J ^a  

^a Novartis Oncology Medical Department   (Argentina)

Author keywords

Breast cancer; Cancer; Clinical trials; Immunotherapy; Melanoma; Vaccines

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; BREAST TUMOR; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; IMMUNOLOGY; MELANOMA; METHODOLOGY; NEOPLASM; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA; NEOPLASMS;

EID: 3442880456     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Greenberg PD: Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 49:281-355.
2. Schreiber H, Ward PL, Rowley DA, Stauss HJ: Unique tumor-specific antigens. Annu Rev Immunol (1988) 6:465-483.
3. Greenberg PD, Cheever MA, Fefer A: H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol (1981) 126(6):2100-2103.
4. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 233(4770):1318-1321.
5. Shimizu K, Shen FW: Role of different T cell sets in the rejection of syngeneic chemically induced tumors. J Immunol (1979) 122(3):1162-1165.
6. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 19(9):2370-2380.
7. Mitchell MS: Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol (1998) 25(6):623-635.
8. Ibrahim NK, Murray JL: Clinical development of the STn-KLH vaccine (Theratope®). Clin Breast Cancer (2003) 3(Suppl 4):S139-S143.
9. Huang K, Lin S: Nationwide vaccination: A success story in Taiwan. Vaccine (2000) 18(Suppl 1):S35-S38.
10. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Proof of Principle Study Investigators: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 347(21):1645-1651.
11. Wang RF: The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol (2001) 22(5):269-276.
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 4(3):321-327.
13. Van den Eynde BJ, van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol (1997) 9(5):684-693.
14. Livingston PO, Ragupathi G, Musselli C: Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J Clin Immunol (2000) 20(2):85-93.
15. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol (1999) 1(6):362-368.
16. Wells AD, Malkovsky M: Heat shock proteins, tumor immunogenicity and antigen presentation: An integrated view. Immunol Today (2000) 21(3):129-132.
17. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol (2002) 3(11):991-998.
18. Johnsen AK, Templeton DJ, Sy M, Harding CV: Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol (1999) 163(8):4224-4231.
19. Franksson L, George E, Powis S, Butcher G, Howard J, Karre K: Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. J Exp Med (1993) 177(1):201-205.
20. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A: Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today (1999) 20(4):158-160.
21. Heitger A, Ladisch S: Gangliosides block antigen presentation by human monocytes. Biochim Biophys Acta (1996) 1303(2):161-168.
22. Garofalo T, Sorice M, Misasi R, Cinque B, Giammatteo M, Pontieri GM, Cifone MG, Pavan A: A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. Involvement of serine phosphorylation and protein kinase C translocation. J Biol Chem (1998) 273(52):35153- 35160.
23. McKallip R, Li R, Ladisch S: Tumor gangliosides inhibit the tumor-specific immune response. J Immunol (1999) 163(7):3718- 3726.
24. Halak BK, Maguire HC Jr, Lattime EC: Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res (1999) 59(4):911-917.
25. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, Mantovani A: IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol (1998) 28(1):359-369.
26. Kanda N: Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun (1999) 256(1):41-44.
27. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother (1998) 21(4):295-306.
28. Ockert D, Schmitz M, Hampl M, Rieber EP: Advances in cancer immunotherapy. Immunol Today (1999) 20(2):63-65.
29. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol (1990) 8(11):1858-1867.
30. Elliott GT, McLeod RA, Perez J, Von Eschen KB: Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol (1993) 9(3):264-272.
31. Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol (1997) 15(6):2359-2370.
32. Engleman EG: Dendritic cell-based cancer immunotherapy. Semin Oncol (2003) 30(3 Suppl 8):23-29.
33. Liu MA: Vaccine developments. Nat Med (1998) 4(5 Suppl):515-519.
34. Polo JM, Dubensky TW Jr: DNA vaccines with a kick. Nat Biotechnol (1998) 16(6):517-518.
35. Herlyn D, Birebent B: Advances in cancer vaccine development. Ann Med (1999) 31(1):66-78.
36. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN: Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA (1996) 93(25):14809-14814.
37. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 2(1):52-58.
38. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S: Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res (1995) 1(7):705-713.
39. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol (2000) 18(2):376-384.
40. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB: Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res (1999) 5(1):77-81.
41. Knutson KL: GMK, Progenics. Curr Opin Investig Drugs (2002) 3(1):159-164.
42. MGV, Progenics. Investigational Drugs database (2003) December.
43. Melacine. Investigational Drugs database (2003) December.
44. M-Vax. Investigational Drugs database (2003) December.
45. Park SH, Bendelac A: CD1-restricted T-cell responses and microbial infection. Nature (2000) 406(6797):788-792.
46. Deng W, Li R, Ladisch S: Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst (2000) 92(11):912-917.
47. Hamilton WB, Helling F, Lloyd KO, Livingston PO: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer (1993) 53(4):566-573.
48. Kiura K, Watarai S, Ueoka H, Tabata M, Gemba K, Aoe K, Yamane H, Yasuda T, Harada M: An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line. Anticancer Res (1998) 18(4C):2957-2960.
49. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO: Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer (2000) 85(5):659-666.
50. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, Sierra GV, Fernandez LE: Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine (1999) 18(1-2):190-197.
51. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J et al: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 21(4):624-630.
52. van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ: Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res (2002) 8(5):1019-1027.
53. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol (2000) 18(23):3964-3973.